| Project/Area Number |
04557066
|
|---|
| Research Category |
Grant-in-Aid for Developmental Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
OCHI Takahiro Osaka Univ. Medicine Professor, 医学部, 教授 (80112035)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OWAKI Hajime Osaka Univ. Medicine Assistant professor, 医学部, 助手 (60223872)
KIMURA Tomoatu Osaka Univ. Medicine Lecturer, 医学部, 講師 (80167379)
脇谷 滋之 大阪大学, 医学部, 助手 (70243243)
小野 啓郎 大阪大学, 医学部, 教授 (70028330)
|
|---|
| Project Period (FY) |
1992 – 1994
|
| Project Status |
Completed (Fiscal Year 1994)
|
| Budget Amount *help |
¥12,000,000 (Direct Cost: ¥12,000,000)
Fiscal Year 1994: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1993: ¥2,800,000 (Direct Cost: ¥2,800,000)
Fiscal Year 1992: ¥8,600,000 (Direct Cost: ¥8,600,000)
|
|---|
| Keywords | Rheumatoid arthritis / Oncofetal membrane marker / Carbohydrate / Sensitization |
|---|
| Research Abstract |
As reported by us, a new myeloid cell population with an oncofetal membrane marker, dimeric Lex (di-Lex ; III3FucV3FucnLc6) , was found in the epiphyseal bone marrow adjacent to the involved joints of patients with severe rheumatoid arthritis (RA) .Patients with RA recieved intradermal (id) injections of di-Lex incorporated in liposome or of high molecular weight glycoprotein, or tumor assosiated carbohydrate antigen (TCA) , containing the same carbohydrate epitope as di-Lex. The epiphyseal myeloid cells were reduced or sometimes eliminated during id injection. In random trials of id injection, observation under clinical and laboratory conditions showed improvement in 63% (17/27) of the patients treated for 6 months with appropriate doses of di-Lex (III3FucnLc4) , and in 72% (31/43) of those treated with an identical protocol for TCA.However, id injection with monomeric Lex had no effect.
|
